Synthetix Inc

Provider Profile Name: Synthetix Inc (operating as Helix Chemical Supply)
Website: helixchemicalsupply.com (non-operational as of December 2024)
Provider Type: Research Peptide Vendor
FDA Warning Letter: February 2024

Operating Details

• E-commerce peptide vendor
• Operated under the website Helix Chemical Supply, marketing semaglutide and tirzepatide “for research purposes”
• No prescription required for purchase
• Received an FDA warning letter in February 2024 for selling non-FDA-approved semaglutide and tirzepatide
• Website was non-operational as of December 18, 2024 — the company appears to have ceased operations following the FDA warning

About the Company

The FDA sent warning letters to Synthetix Inc. for selling unapproved and misbranded versions of GLP-1 therapies semaglutide and tirzepatide. Synthetix, operating under the website Helix Chemical Supply, marketed semaglutide and tirzepatide “for research purposes” — but the FDA argued that evidence on its website contradicted this claim, with the agency stating directly: “Evidence obtained from your website establishes that your products are intended to be drugs for human use.”

Synthetix Inc. received its FDA warning letter approximately ten months before the second wave of enforcement actions in December 2024 that targeted Prime Peptides, Swiss Chems, Summit Research, and Xcel Peptides — making Synthetix among the earliest vendors in this review series to face formal FDA action over unapproved GLP-1 products. Synthetix Inc. labeled its drugs as research chemicals “not for human consumption,” but their websites made it clear they were selling the products to individuals seeking weight loss treatment.

Synthetix’s website was not operational as of December 18, 2024 — approximately ten months after receiving the FDA warning letter. Whether the company shut down voluntarily in response to the enforcement action, ceased operations for other reasons, or is operating under a different name or URL is unknown at time of writing. Patients should not attempt to locate or purchase from Synthetix Inc. under any branding.

The violations documented in Synthetix’s case are part of a broader documented pattern. Connecticut reached a settlement with “Triggered Brand,” a self-described bootleg GLP-1 distributor that allegedly sold raw semaglutide and tirzepatide powders directly to consumers — marketing them as “research-grade” while providing instructions for dissolving, mixing, and self-injecting the powder, without prescription requirements, sterility controls, or adequate assurance regarding potency or stability. Synthetix’s operations followed the same structural model.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

The human safety stakes of this vendor category are not theoretical. The FDA has documented fraudulent compounded semaglutide and tirzepatide containing false information on product labels — including cases where compounding pharmacies identified on product labels do not exist, and cases where the labels of fraudulent compounds contain the name of a licensed pharmacy that did not actually compound the product. Consumers purchasing from unregulated research peptide vendors have no mechanism to verify the authenticity, purity, concentration, or sterility of what they receive.

GLP-1 Offerings and Pricing

At the time of the FDA warning letter, Synthetix Inc.’s Helix Chemical Supply website sold injectable semaglutide and tirzepatide labeled as research chemicals, without requiring a prescription. No licensed prescriber reviewed patient eligibility before or after purchase. No clinical oversight, dosing guidance, titration support, or patient safety monitoring was associated with any product.

Pricing at research peptide vendors in this category is typically well below licensed telehealth compounded GLP-1 programs. The cost differential does not represent superior value — it reflects the complete absence of physician oversight, pharmacy accreditation, quality assurance, clinical safety infrastructure, and regulatory compliance. With the website non-operational, no current pricing data is available or relevant.

Reviews from Trustpilot and Google

No independent Trustpilot, Google, or consumer health review pool was identified for Synthetix Inc. or Helix Chemical Supply at time of writing. The website’s non-operational status as of late 2024 means no ongoing consumer experience can be reported or evaluated.

Compounding Pharmacies Used

Synthetix Inc. did not operate through the 503A or 503B compounding pharmacy framework. Products were manufactured and sold as research chemicals with no disclosed manufacturing source, quality testing methodology, or pharmacy licensure verifiable by consumers. No sterility testing, Certificate of Analysis process, or regulatory oversight applicable to licensed compounding pharmacies was associated with the operation.

Note: Synthetix Inc., operating as Helix Chemical Supply, received an FDA warning letter in February 2024 for selling unapproved and misbranded semaglutide and tirzepatide — products marketed as “for research purposes only” while being sold to consumers seeking human weight loss treatment. The company’s website was non-operational by December 2024, approximately ten months after the warning letter, suggesting the enforcement action led to cessation of operations. Synthetix Inc. had no licensed prescriber network, and did not operate through licensed compounding pharmacies. Patients seeking GLP-1 treatment should use a licensed telehealth provider with a board-certified prescriber and 503A or 503B pharmacy sourcing.